Precision 're'arming of CD33 antibodies

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy with significant unmet therapeutic needs.
• Targeted therapies are emerging as promising strategies for AML treatment.
• CD33 is a well-established target in AML, expressed on most leukemic blasts.

Purpose of the Study:

• To evaluate the preclinical activity of SGN-CD33A, a novel anti-CD33 antibody-drug conjugate (ADC).
• To assess the efficacy of SGN-CD33A against acute myeloid leukemia (AML) cells in vitro and in vivo models.

Main Methods:

• SGN-CD33A is a humanized anti-CD33 monoclonal antibody conjugated to a potent pyrrolobenzodiazepine (PBD) dimer via a protease-cleavable linker.
• In vitro studies involved assessing cytotoxicity and cellular effects on AML cell lines.
• In vivo studies utilized relevant AML xenograft models to evaluate anti-tumor activity and tolerability.

Main Results:

• SGN-CD33A demonstrated potent and specific cytotoxicity against a range of AML cell lines in vitro.
• The ADC exhibited significant anti-leukemic activity in vivo, leading to tumor regression and improved survival in preclinical models.
• Pharmacokinetic and pharmacodynamic analyses supported the proposed mechanism of action.

Conclusions:

• SGN-CD33A exhibits promising preclinical anti-leukemic activity against AML.
• The data support the further clinical development of SGN-CD33A as a targeted therapy for AML patients.